the adder
21 years ago
Peptech releases half-year results
Australian biotechnology company, Peptech Limited has released its results for
the half year ended 31 March 2003 with total revenues for the period of $2.9
million, compared to $3.5 million in the previous corresponding period.
The result for the half-year was an operational loss of $2.2 million plus a noncash
Domantis amortisation expense of $3.5 million resulting in a net loss of
$5.7 million. In the previous corresponding half-year, the operational loss was
$2.5 million with the non-cash Domantis amortisation expense of $1.7 million
resulting in a net loss of $4.2 million. With the tax charge ($0.5 million) and the
large foreign exchange losses ($0.9 million) of the previous corresponding halfyear
not being repeated in this half-year, the operational loss was slightly
reduced.
Managing Director, Mr Stephen Kwik said the current dispute with Centocor, a
subsidiary of Johnson and Johnson, over royalty payments as well as an
increase in the amortisation charge of research payments with antibody
company, Domantis had significantly impacted on the result.
Royalty revenues decreased from $1.4 million to $0.8 million and the
amortisation charge with Domantis was $3.5 million, an increase of
$1.8 million over the previous corresponding period.
“Peptech is committed to enforcing its intellectual property rights and is taking
all necessary steps to protect our shareholders’ interests,” Mr Kwik said.
“In addition, the amortisation charge for Peptech’s collaborative research
program with Domantis reflects the conservative policy adopted by the Board,
with all research payments being fully expensed by April 2004, well in advance
of any direct commercial benefits being received.”
In February this year Peptech made its final research ($4.8 million) and equity
($3.4 million) payments to Domantis - fulfilling all of its current obligations to the
company. Peptech now holds a 36.1% interest in Domantis or 31.4% should
all options currently issued by Domantis be exercised.
Mr Kwik said the recent announcement that a domain antibody against tumour
necrosis factor (TNF) has proven effective in an industry-accepted model by
completely preventing the onset of arthritis is a glowing endorsement of the
technology and a very significant advance in the development of a next
generation of antibody therapeutics. For Peptech it could represent a significant
step towards bringing our anti-TNF domain antibody into the clinic.
During the reporting period, health care company, Abbott Laboratories received
approval in the USA to market its product HumiraÆË and had also recently
received a positive opinion for the marketing of the product in Europe. Upon
European marketing approval, Peptech can expect to receive a second
milestone payment, as its key anti-TNF intellectual property has been nonexclusively
licensed to Abbott.
In Peptech Animal Health (PAH), sales of OvuplantÆÊ continued to be strong,
but were slightly lower than last year as the company's Canadian distributor did
not place a repeat order due to over-ordering in the prior year.
PAH also received approval in New Zealand to market SuprelorinÆÊ, a male dog
contraceptive product. Approval of a similar product from Australian authorities
is expected in the near future.
This is a key milestone in the company's development as an independent
review has found that the product is effective, safe and meets all criteria of
registration,Mr Kwik said. ¡§It also demonstrates that our Animal Health drug
delivery technology can be developed into approvable products.
Peptech is continuing discussions with global pharmaceutical companies
regarding the commercialisation and ongoing development of Peptech's series
of domestic, companion animal contraceptive products.
At 31 March 2003, the company had cash resources of $13.6 million. In
January 2003 the company undertook a successful and well-received share
placement of 6.625 million shares at $1.55 per share, raising gross proceeds of
$10.3 million.
Further information:
Mr Stephen Kwik Dr Paul Schober
Managing Director Investor Relations
Peptech Limited Peptech Limited
Bryce
21 years ago
There is confidence in Peptech, only 257,798 traded at 10.30, We have seen much worst in the past with better reports.
Obviously the report has not caused to much concern as yet.
Stock Bid $ Offer $ Last $ Change* Open $ High $ Low $ Volume News
PTD 1.650 1.660 1.660 -0.040 1.670 1.680 1.640 257,798
Where is everyone, believe me the site is extremely well managed, There is a LOK site here as well with the crew from Oze. If you have any LOK the board is called LOOK.
We should get some tips happening. Good to see you around Itm54
itm54au
21 years ago
Unimpressive 1/2 yearly from PTD, $4.2m loss.
I take it they use US dates here, so its a long time between drinks here. Thanks Bryce for bringing the site to my attention.
I suppose a loss of that size was expected, but I sure won't be rushing out to buy after those figures. On the positive side, the rapid amortisation policy is a bit like wiping the slate clean so that there are no shackles when the next good news is released.
Keep an eye on Namakwa NDC, cheap little diamond stock that's starting to move again.
the adder
21 years ago
Here we are bryce having a look around might just post the progress of the Japanese patent straight from the JPO site
Translated to English....first page.
Credit to hopeful2 from the ozestock site.
Here it is:
Looks like a publication to me registration/patent to come.
(19) [Country of Issue] Japan Patent Office (JP)
(12) [Official Gazette Type] Open patent official report (A)
(11) [Publication No.] JP,2003-96096,A (P2003-96096A)
(43) [Date of Publication] April 3, Heisei 15 (2003. 4.3)
(54) [Title of the Invention] Tumor necrosis factor joint ligand.
(51) [The 7th edition of International Patent Classification]
C07K 14/47 ZNA . A61K 45/00 . A61P 35/00 . 35/02 . //C07K 16/24 ZTD . C12P 21/08 .
[FI]
C07K 14/47 ZNA . A61K 45/00 . A61P 35/00 . 35/02 . C07K 16/24 ZTD . C12P 21/08 .
[Request for Examination] ****
[The number of claims] 31.
[Mode of Application] OL.
[Number of Pages] 29.
(21) [Filing Number] Application for patent 2002-234004 (P2002-234004)
(62) [Divisional Application] Division of Japanese Patent Application No. 2-510780.
(22) [Filing Date] August 7, Heisei 2 (1990. 8.7)
(31) [Priority Document Number] PJ5662.
(32) [Priority Date] August 7, Heisei 1 (1989. 8.7)
(33) [Country Declaring Priority] Australia (AU)
(31) [Priority Document Number] PJ7576.
(32) [Priority Date] November 24, Heisei 1 (1989. 11.24)
(33) [Country Declaring Priority] Australia (AU)
(71) [Applicant]
[Identification Number] 500468537.
[Name] PEPUTEKKU Limited.
[Address] Australia Nu South Wales 2113 North RAIDO Waterloo Loading 35-41.
(72) [Inventor(s)]
[Name] Deborah Ann lath JIEN.
[Address] Australia country 2120 ENUESU W Sone lei EDDI Street 4.
(72) [Inventor(s)]
[Name] Roger Aston.
[Address] Australia country 2120 ENUESU W Waist Pennant HIRUZU Highness Loading 2430 Lot.
(74) [Attorney]
[Identification Number] 100064908.
[Patent Attorney]
[Name] Shiga Masatake (besides one person)
[Theme code (reference)]
Four B064. 4C084. 4H045.
[F term (reference)]
4B064 AG27 CA19 CA20 DA01. 4C084 AA17 NA14 ZB262 ZB272. 4H045 AA10 AA30 bus-available10 EA20 FA33 FA58 FA59 FA61 GA25.
--------------------------------------------------------------------------------
[Translation done.]
* NOTICES *
Japan Patent Office is not responsible for any damages caused by the use of this translation.
1. This document has been translated by computer.So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3.In the drawings, any words are not translated.
(57) [Abstract]
[Technical problem] The antibody which checks alternatively the activity from which TNF alpha differs, or promotes it.
[Means for Solution] They are ligands, such as a specific monoclonal antibody, to the TOPOGURAFIKKU field where TNF alpha differs. If these ligands are combined with TNF, neoplasm degradation, guidance of an inner-bark procoagulant, guidance of neoplasm fibrin deposition, cytotoxicity, and the activity of acceptor combination will be influenced alternatively. As a desirable example of a ligand, an antibody, F (ab) fragment, a reconstruction antibody (CDR transplant hominization antibody) single domain antibody (dAbs), a single chain antibody, blood serum binding protein, an acceptor, etc. are mentioned.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Hot Features
Premium
